Table Graph
      published meta-analysis   sensitivity analysis   studies

placebo in COVID 19 all comers - Summary of results

OutcomeTE95% CInkI2ROBPub. bias death or transfer to ICUdetailed resultsBACC Bay Tocilizumab Trial, 2020 (REV) 1.03 [0.53; 2.00] 1.03[0.53; 2.00]BACC Bay Tocilizumab Trial, 2020 (REV)10%242NAnot evaluable deathsdetailed resultsBACC Bay Tocilizumab Trial, 2020 (REV) 0.66 [0.18; 2.43] 0.66[0.18; 2.43]BACC Bay Tocilizumab Trial, 2020 (REV)10%242NAnot evaluable clinical deteriorationdetailed resultsBACC Bay Tocilizumab Trial, 2020 (REV) 0.90 [0.48; 1.70] 0.90[0.48; 1.70]BACC Bay Tocilizumab Trial, 2020 (REV)10%242NAnot evaluable clinical improvementdetailed resultsBACC Bay Tocilizumab Trial, 2020 (REV) 0.94 [0.71; 1.25] 0.94[0.71; 1.25]BACC Bay Tocilizumab Trial, 2020 (REV)10%242NAnot evaluable death or ventilationdetailed resultsBACC Bay Tocilizumab Trial, 2020 (REV) 1.20 [0.55; 2.63] 1.20[0.55; 2.63]BACC Bay Tocilizumab Trial, 2020 (REV)10%242NAnot evaluable serious adverse eventsdetailed resultsBACC Bay Tocilizumab Trial, 2020 (REV) 0.83 [0.40; 1.72] 0.83[0.40; 1.72]BACC Bay Tocilizumab Trial, 2020 (REV)10%242NAnot evaluable0.52.01.0relative treatment effectwww.metaEvidence.org2024-07-15 15:46 +02:00

TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers); k: number of studies; n: total number of patients; ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1; studied treatment is better when TE < 1;

pathologies: 94 - treatments: 650 - roots T: 650

- About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy - Licence Creative Commons